Synthetic efforts to overcome the metabolic oxidative degradation of the HIV protease inhibitory cyclic urea DMP323, a benzyl alcohol, have led to the discovery of a tertiary carbinol with superior affinity for the viral protease and more potent inhibitory activity against viral replication. Synthetic approaches to this new carbinol and comparative analysis of its pharmacology and pharmacokinetics are presented.